Mehran Taban is an Ophthalmology physician affiliated with Retina Macula Institute. OpenAlex indexes 52 publications with 2,229 citations (h-index 21).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
20528 Hawthorne Blvd Ste 201
Torrance, CA 905033271
Telephone
424-247-9090Provider last certified this registry record 30 Jan 2023.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20252 payments
- Ocular Therapeutix, Inc.Program year20255 payments
- Alcon Vision LLCProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
78.7%Antineovascularisation agents51.5%Faricimab-svoa100%Part B, office-administered≥30 patientsFluoroquinolone Antibacterial10.6%Ciprofloxacin Hcl100%Part D≥562 patients+ 9 more classes in this area
Dermatology
10.8%Corticosteroid10.8%Triamcinolone acetonide100%Part B, office-administered≥32 patientsCancer & immunology
8.5%Complement Inhibitor6.4%Pegcetacoplan100%Part B, office-administered≥17 patientsVascular Endothelial Growth Factor Inhibitor2%Aflibercept100%Part B, office-administered≥39 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Subchoroidal Release of VEGF and bFGF Produces Choroidal Neovascularization in Rabbit
Current Eye Research
2016 - Topical difluprednate for treatment of serous retinal detachment and panuveitis associated with Vogt-Koyanagi-Harada disease
Digital Journal of Ophthalmology
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Richard Spaide, MD
Vitreous Retina Macula Consultants of New York
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”